The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration

Brain

Volumn 134, Issue 11, 2011, Pages 3146-3166

  Cummings, Jeffrey L ^a   Henchcliffe, Claire ^b   Schaier, Sharon ^c   Simuni, Tanya ^d   Waxman, Alan ^e   Kemp, Paul ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL CENTER   (United States)

^c PAREXEL INTERNATIONAL   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e LAC USC MEDICAL CENTER   (United States)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Alzheimer's disease; dementia with Lewy bodies; dopaminergic imaging; neurodegeneration; Parkinson's disease

Indexed keywords

DOPAMINE TRANSPORTER; IOFLUPANE I 123;

ALZHEIMER DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIFFUSE LEWY BODY DISEASE; DISEASE CLASSIFICATION; DOPAMINERGIC SYSTEM; EARLY DIAGNOSIS; ESSENTIAL TREMOR; HUMAN; NERVE DEGENERATION; NEUROIMAGING; NEUROLOGIC DISEASE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 81055125527     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr177     Document Type: Review

References (167)

1. Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci 2010; 289: 18-22.
2. Abbott RD, Ross GW, White LR, Tanner CM, Masaki KH, Nelson JS, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005; 65: 1442-6. (Pubitemid 41552777)
3. Adams JR, van Netten H, Schulzer M, Mak E, Mckenzie J, Strongosky A, et al. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005; 128 (Pt 12): 2777-85. (Pubitemid 41746632)
4. Adbo WF, Borm GF, Munneke M, Verbeek MM, Esselink RA, Bloem BR. Ten steps to identify atypical parkinsonism. J Neurol Neurosurg Psychiatry 2006; 77: 1367-9. (Pubitemid 44851998)
5. Anon. Biomarker promise for Parkinson's disease. Lancet Neurol 2010; 9: 1139.
6. Antonini A, Leenders KL, Vontobel P, Maguire RP, Missimer J, Psylla M, et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120 (Pt 12): 2187-95. (Pubitemid 28014595)
7. Antonini A, Moresco RM, Gobbo C, De Notaris R, Panzacchi A, Barone P, et al. The status of dopamine nerve terminal in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FE-CIT. Neurol Sci 2001; 22: 47-8. (Pubitemid 32622268)
8. Antonini A, Benti R, De Notaris R, Tesei S, Zecchinelli A, Sacilotto G, et al. 123I-ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 2003; 24: 149-50. (Pubitemid 37304286)
9. Arnold G, Tatsch K, Kraft E, Oertel WH, Schwarz J. Steele-Richardson- Olszewski-syndrome: reduction of dopamine D2 receptor binding relates to the severity of midbrain atrophy in vivo: (123)IBZM SPECT and MRI study. Mov Disord 2002; 17: 557-62. (Pubitemid 36061167)
10. Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brü cke T. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Trans 1998; 105: 1213-28. (Pubitemid 29017402)
11. Benaderette S, Zanotti Fregonara P, Apartis E, Nguyen C, Trocello JM, Remy P, et al. Psychogenic Parkinsonism: a combination of clinical, electrophysiological, and [123I]-FP-CIT SPECT scan explorations improves diagnostic accuracy. Mov Disord 2006; 21: 310-7.
12. Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of Parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT Study Group. Mov Disord 2000; 15: 503-10. (Pubitemid 30333223)
13. Berding G, Brü cke T, Odin P, Brooks DJ, Kolbe H, Gielow P, et al. [123I]beta-CIT SPECT imaging in dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy. Nuklearmedizin 2003; 42: 31-8. (Pubitemid 36231689)
14. Berendse HW, Ponsen MM. Diagnosing premotor Parkinson's disease using a two-step approach combining olfactory testing and DAT SPECT imaging. Parkinsonism Relat Disord 2009; 15 (Suppl. 1): S26-30.
15. Booij J, Kemp P. Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs. Eur J Nucl Med Mol Imaging 2008; 35: 424-38.
16. Booij J, Tissingh G, Winogrodzka A, Boer GJ, Stoof JC, Wolters EC, et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997; 24: 68-71. (Pubitemid 27122444)
17. Booij J, Speelman JD, Horstink MW, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med 2001; 28: 266-72.
18. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211. (Pubitemid 36007810)
19. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001; 11: 351-5. (Pubitemid 34461714)
20. Breit S, Reimold M, Reischi G, Klockgether T, Wü llner U. [11C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. J Neural Transm 2006; 113: 187-93. (Pubitemid 43121754)
21. Brooks DJ. Diagnosis and management of atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2002; 72: i10-6.
22. Brooks DJ, Ibanez V, Sawle GV, Quinn N, Lees AJ, Mathias CJ, et al. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-55. (Pubitemid 20359162)
23. Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, et al. Striatal D2 receptor status in patients with Parkinson's disease, striato-nigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 1992; 31: 184-92.
24. Brooks DJ. Neuroimaging in Parkinson's disease. NeuroRx 2004; 1: 243-54. (Pubitemid 46613776)
25. 123, I]beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl, 1997; 50, 9-24.
26. Burn DJ, Brooks DJ. Nigral dysfunction in drug-induced Parkinsonism: an 18F-dopa PET study. Neurology 1993; 43: 552-6. (Pubitemid 23088491)
27. Burn DJ, Sawle GV, Brooks DJ. Differential diagnosis of Parkinson's disease, multiple system atrophy, and Steele-Richardson-Olszewski syndrome: discriminant analysis of striatal 18F-dopa PET data. J Neurol Neurosurg Psychiatr 1994; 57: 278-84. (Pubitemid 24083410)
28. Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D. Dementia and survival in Parkinson disease a 12-year population study. Neurology 2008; 70: 1017-22. (Pubitemid 351451309)
29. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123-ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord 2004; 19: 1175-82. (Pubitemid 39433368)
30. Ceravolo R, Volterrani D, Gambaccini G, Bernardini S, Rossi C, Logi C, et al. Presynaptic nigrostriatal function in a group of Alzheimer's disease patients with Parkinsonism: evidence from a dopamine transporter imaging study. J Neural Transm 2004; 111: 1065-73. (Pubitemid 39037127)
31. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010; 67: 715-23.
32. Clarke CE. A 'cure' for Parkinson's disease: can neuroprotection be proven with current trial designs? Mov Disord 2004; 19: 491-8.
33. Cohen O, Pullman S, Jurewicz E, Watner D, Louis ED. Rest tremor in patients with essential tremor: prevalence, clinical correlates, and elec-trophysiologic characteristics. Arch Neurol 2003; 60: 405-10. (Pubitemid 36314367)
34. Colloby SJ, O'Brien JT, Fenwick JD, Firbank MJ, Burn DJ, McKeith IG, et al. The application of statistical parametric mapping to 123I-FP-CIT SPECT in dementia with Lewy bodies, Alzheimer's disease and Parkinson's disease. Neuroimage 2004; 23: 956-66. (Pubitemid 39446529)
35. Colloby SJ, Williams ED, Burn DJ, Lloyd JJ, McKeith IG, O'Brien JT. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging 2005; 32: 1176-85. (Pubitemid 41355944)
36. Colloby SJ, Firbank MJ, Pakrasi S, Lloyd JJ, Driver I, McKeith IG, et al. A comparison of 99mTc-exametazime and 123I-FP-CIT-SPECT imaging in the differential diagnosis of Alzheimer's disease and dementia with Lewy bodies. Int Psychogeriatr 2008; 20: 1124-40.
37. Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 2010; 37: 443-50.
38. Diaz-Corrales FJ, Sanz-Viedma S, Garcia-Solis D, Escobar-Delgado T, Mir P. Clinical features and 123I-FP-SPECT imaging in drug-induced Parkinsonism and Parkinson's disease. Eur J Med Mol Imaging 2010; 37: 556-64.
39. Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson's disease. Mov Disord 2009; 24: 793-800.
40. Doepp F, Plotkin M, Siegal L, Kivi A, Gruber D, Lobsien E, et al. Brain parenchyma sonography and 123I-FP-CIT in Parkinson's disease and essential tremor. Mov Disord 2008; 23: 405-10.
41. El Fakhri G, Habert MO, Maksud P, Kas A, Malek Z, Kijewski MF, et al. Quantitative simultaneous 99mTc-ECD/123I-FP-CIT SPECT in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2006; 33: 87-92. (Pubitemid 41785314)
42. Eller M, Williams DR. Biological fluid biomarkers in neurodegenerative Parkinsonism. Nat Rev Neurol 2009; 5: 561-70.
43. Eshuis SA, Jager PL, Maguire RP, Jonkman S, Dierckx RA, Leenders KL. Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. Eur J Nucl Med Mol Imaging 2009; 36: 454-62.
44. Esper CD, Factor SA. Failure of recognition of drug-induced Parkinsonism in the elderly. Mov Disord 2008; 23: 401-4.
45. Fahn S, Oakes D, Shoulson I, Kieburtz K, Randolph A, Lang A, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004; 351: 2498-508.
46. Felicio AC, Godeiro-Junior C, Shih MC, Borges V, Silva SM, Aguiar Pde C, et al. Evaluation of patients with clinically unclear parkinsonian syndromes submitted to brain SPECT imaging using the technetium-99 m labelled tracer TRODAT-1. J Neurol Sci 2010a; 291: 64-8.
47. Felicio AC, Godeiro-Junior C, Moriyama TS, Shih MC, Hoexter MQ, Borges V, et al. Degenerative Parkinsonism in patients with psycho-genic Parkinsonism: a dopamine transporter imaging study. Clin Neurol Neurosurg 2010b; 112: 282-5.
48. Gaig C, Mart́ MJ, Tolosa E, Valldeoriola F, Paredes P, Lomeña FJ, et al. 123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism. Mov Disord 2006; 21: 1994-8. (Pubitemid 44848954)
49. Gerschlager W, Bencsits G, Pirker W, Bloem BR, Asenbaum S, Prayer D, et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord 2002; 17: 518-23. (Pubitemid 36040965)
50. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002; 73: 517-23. (Pubitemid 35246803)
51. Gilman S, Koeppe RA, Little R, An H, Junck L, Giordani B, et al. Striatal monoamine terminals in Lewy body dementia and Alzheimer's disease. Ann Neurol 2004; 55: 774-80. (Pubitemid 38702572)
52. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-6.
53. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE, et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008; 71: 903-10.
54. Hambÿe AS, Vervaet A, Dethy S. FP-CIT SPECT in clinically inconclusive Parkinsonian syndrome during amiodarone treatment: a study with follow-up. Nucl Med Commun 2010; 31: 583-9.
55. Hanyu H, Shimizu S, Hirao K, Sakurai H, Iwamoto T, Chikamori T, et al. The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord 2006; 22: 379-84. (Pubitemid 44726006)
56. Hauser RA. New considerations in the medical management of early Parkinson's disease: impact of recent clinical trials on treatment strategy. Parkinsonism Relat Disord 2009; 15 (Suppl. 3): S17-21.
57. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 23: 837-44.
58. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-22.
59. Hu XS, Okamura N, Arai H, Higuchi M, Matsui T, Tashiro M, et al. 18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000; 55: 1575-7.
60. Huang WS, Chiang YH, Lin JC, Chou YH, Cheng CY, Liu RS. Crossover study of 99mTc-TRODAT-1 SPECT and 18F-FDOPA PET in Parkinson's disease patients. J Nucl Med 2003; 44: 999-1005.
61. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181-4.
62. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002; 125: 861-70. (Pubitemid 34279780)
63. Hwang WJ, Yao WJ, Wey SP, Ting G. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med 2004; 45: 207-13. (Pubitemid 47618638)
64. Isaias IU, Marotta G, Hirano S, Canesi M, Benti R, Righini A, et al. Imaging essential tremor. Mov Disord 2010; 25: 679-86.
65. Jain S, Lo SE, Louis ED. Common misdiagnosis of a common neurological disorder: how are we misdiagnosing essential tremor? Arch Neurol 2006; 63: 1100-4. (Pubitemid 44232315)
66. Jennings DL, Seibyl JP, Oakes D, Eberly S, Murphy J, Marek K. 123I b-CIT and single-photon emission computed tomographic imaging vs clinical evaluation in Parkinsonian syndrome: unmasking a diagnosis. Arch Neurol 2004; 61: 1224-9. (Pubitemid 39062674)
67. Jennings DL, Tabamo RT, Seibyl JS, Marek KM. InSPECT: Investigating the effect of short-term treatment with pramipexole or levodopa on [123I]b-CIT and SPECT imagingThe 11th International Congress of Parkinson's Disease and Movement Disorders, Istanbul 2007. Abstract 465.
68. Kalra S, Grosset DG, Benamer HT. Differentiating vascular Parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord 2010; 25: 49-56.
69. Kemp PM, Holmes C. Imaging in dementia with Lewy bodies: a review. Nucl Med Commun 2007; 28: 511-9. (Pubitemid 46848642)
70. Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked Parkinsonism: an 18F-dopa PET study. Ann Neurol 2002; 52: 849-53. (Pubitemid 35403199)
71. Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002; 17: 303-12. (Pubitemid 36041299)
72. Kish SJ, Shannak K, Hirnykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiological and clinical implications. N Engl J Med 1988; 318: 876-56.
73. Klein JC, Eggers C, Kalbe E, Weisenbach S, Hohmann C, Vollmar S, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885-92.
74. Koeppe RA, Gilman S, Junck L, Wernette K, Frey KA. Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+ )-[11C] dihydrotetrabenzine positron emission tomography. Alzheimers Dement 2008; 4 (1 Suppl. 1): S67-76.
75. Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2004; 31: 1631-8. (Pubitemid 40104609)
76. Lang AE, Koller WC, Fahn S. Psychogenic parkinsonism. Arch Neurol 1995; 52: 802-10.
77. Lees AJ. Trauma and Parkinson disease. Rev Neurol 1997; 153: 541-6.
78. Lim SM, Katsifis A, Villemagne VL, Best R, Jones G, Saling M, et al. The 18F-FDG PET cingulated island sign and comparison to 123I-beta-CIT SPECT for diagnosis of dementia with Lewy bodies. J Nucl Med 2009; 50: 1638-45.
79. Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 2003; 18: 467-86. (Pubitemid 36656531)
80. Lorberboym M, Djaldetti R, Melamed E, Sadeh M, Lampl Y. 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovas-cular disease and clinical diagnosis of vascular parkinsonism. J Nucl Med 2004; 45: 1688-93. (Pubitemid 47618476)
81. Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellman M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson's disease. Mov Disord 2006; 21: 510-4.
82. Louis ED. Essential tremors: a family of neurodegenerative disorders? Arch Neurol 2009; 66: 1202-8.
83. Louis ED, Asabere N, Agnew A, Moskowitz CB, Lawton A, Cortes E, et al. Rest tremor in advanced essential tremor: a post-mortem study of nine cases. J Neurol Neurosurg Psychiatry 2011; 82: 261-5.
84. Lu CS, Weng YH, Chen MC, Chen RS, Tzen KY, Wey SP, et al. 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med 2004; 45: 49-55.
85. Lubarsky M, Juncos JL. Progressive supranuclear palsy: a current review. Neurologist 2008; 14: 79-88. (Pubitemid 351366940)
86. Mahapatra RK, Edwards MJ, Schott JM, Bhatia KP. Corticobasal degeneration. Lancet Neurol 2004; 3: 736-43. (Pubitemid 39535259)
87. Marek K, Jennings D. Can we image premotor Parkinson disease? Neurology 2009; 72 (Suppl. 2): S21-6.
88. Marek K, Jennings D, Seibyl J. Long-term follow-up of patients with scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA study. Neurology 2005; 64 (Suppl. 1): A274.
89. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980; 10: 55-72. (Pubitemid 11141134)
90. Marshall VL, Patterson J, Hadley DM, Grosset KA, Grosset DG. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging. Nucl Med Commun 2006; 27: 933-7. (Pubitemid 44706887)
91. Marshall VL, Reininger CB, Marquardt M, Patterson J, Hadley DM, Oertel WH, et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov Disord 2009; 24: 500-8.
92. McKeith I, Fairburn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305: 673-8.
93. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005; 65: 1863-72. (Pubitemid 43970103)
94. McKeith I, O'Brien J, Tatsch K, Booij J, Darcourt J, Padovani A, et al. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007; 6: 305-13. (Pubitemid 46367938)
95. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Aging 1999; 28: 99-102. (Pubitemid 29161211)
96. Merdes AR, Hansen LA, Jeste DV, Galasko D, Hofstetter CR, Ho GJ, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 27: 1568-90.
97. Morrish PK. DAT-SPECTAll that glitters is not gold. http://jnnp.bmj.com/ content/81/1/5/reply (May 27, 2010, date last accessed).
98. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 2008; 49: 390-8. (Pubitemid 351355204)
99. National Institute of Neurological Disorders and StrokeParkinson's disease backgrounderhttp://www.ninds.nih.gov/disorders/parkinsons-disease/ parkinsons-disease-backgrounder.htm (May 27, 2010, date last accessed).
100. Nelson PT, Jicha GA, Kryscio RJ, Abner EL, Schmitt FA, Cooper G, et al. Low sensitivity in clinical diagnosis of dementia with Lewy bodies. J Neurol 2010; 257: 359-66.
101. Newman EJ, Breen K, Patterson J, Hadley DM, Grosset KA, Grosset DG. Accuracy of Parkinson's disease diagnosis in 610 general practice patients in the West of Scotland. Mov Disord 2009; 24: 2379-85.
102. Nikolaus S, Antke C, Mü ller HW. In vivo imaging of synaptic function in the central nervous system I. Movement disorders and dementia. Behav Brain Res 2009; 204: 1-31.
103. Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003; 348: 1356-64. (Pubitemid 36384104)
104. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004; 61: 919-25. (Pubitemid 38747333)
105. O'Brien J, McKeith IG, Walker Z, Tatsch K, Booij J, Darcourt J, et al. Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies. Br J Psychiatry 2009; 194: 34-9.
106. Otsuka M, Ichiya Y, Hosokawa S, Kuwabara Y, Tahara T, Fukumura T, et al. Striatal blood flow, glucose metabolism and 18F-uptake: difference in Parkinson's disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 1991; 54: 898-904.
107. Oyanagi C, Katsumi Y, Hanakawa T, Hayashi T, Thuy DD, Hashikawa K, et al. Comparison of striatal dopamine D2 receptors in Parkinson's disease and progressive supranuclear palsy patients using [123I] iodo-benzofuran single-photon emission computed tomography. J Neuroimaging 2002; 12: 316-24.
108. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. JAMA 2000; 284: 1931-8.
109. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653-61.
110. Parkinson Study Group PRECEPT Investigators. Mixed linage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007; 69: 1480-90.
111. Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson's disease. Biochim Biophys Acta 2009; 1792: 722-9.
112. Pavese N, Khan NL, Scherfler C, Cohen L, Brooks DJ, Wood NW, et al. Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. Mov Disord 2009a; 24: 2260-6.
113. Pavese N, Kiferle L, Piccini P. Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism Relat Disord 2009b; 155: S33-7.
114. Pifarré P, Cuberas G, Hernández J, Lorenzo C, Miquel F, Castell-Conesa J. Cortical and subcortical patterns of I-123 iodobenzamide SPECT in striatal D(2) receptor parkinsonisms. Clin Nucl Med 2010; 35: 228-33.
115. Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain 1999; 122 (Pt 8): 1449-68. (Pubitemid 29374123)
116. Pirker W, Asenbaum S, Bencsits G, Prayer D, Gerschlager W, Deecke L, et al. [123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord 2000; 15: 1158-67.
117. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffman M, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002; 17: 45-53. (Pubitemid 36041259)
118. Plotkin M, Amthauer H, Klaffe S, Kü hn A, Lü demann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of par-kinsonian syndromes: study on 72 patients. J Neural Transm 2005; 112: 677-92. (Pubitemid 40591200)
119. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters ECh, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56: 173-81. (Pubitemid 39037913)
120. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009; 72: 1296-300.
121. Prunier C, Tranquart F, Cottier JP, Giraudeau B, Chalon S, Guilloteau D, et al. Quantitative analysis of striatal dopamine D2 receptors with 123 I-iodolisuride SPECT in degenerative extrapyramidal diseases. Nucl Med Commun 2001; 22: 1207-14. (Pubitemid 33031275)
122. Rajput A, Rozdilsky B, Ang L. Accuracy of clinical diagnosis in parkinson-ism-a prospective study. Can J Neurol Sci 1991; 18: 275-8.
123. Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord 2009; 24 (Suppl. 2): S732-41.
124. Rossi C, Volterrani D, Nicoletti V, Manca G, Frosini D, Kiferle L, et al. "Parkinson-dementia" diseases: a comparison by double tracer SPECT studies. Parkinsonism Relat Disord 2009; 15: 762-6.
125. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007; 68: 1718-25. (Pubitemid 46763260)
126. Samuel W, Caligiuri M, Galasko D, Lacro J, Marini M, McClure FS, et al. Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000; 15: 794-802.
127. Sawle GV, Brooks DJ, Marsden CD, Frackowiak RS. Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 1991; 114 (Pt 1B): 541-56.
128. Scherfler C, Nocker M. Dopamine transporter SPECT: how to remove subjectivity. Mov Disord 2009; 24 (Suppl. 2): S721-4.
129. Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, et al. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain 2005; 128: 1605-12. (Pubitemid 41373679)
130. Schillaci O, Pierantozzi M, Filippi L, Manni C, Brusa L, Danieli R, et al. The effect of levodopa therapy on dopamine transporter SPECT imaging with 123I-FP-CIT in patients with Parkinson's disease. Eur J Nucl Med Mol Imaging 2005; 32: 1452-6. (Pubitemid 41746850)
131. Schneider SA, Edwards MJ, Mir P, Cordivari C, Hooker J, Dickson J, et al. Patients with adult-onset dystonic tremor resembling Parkinsonism tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord 2007; 22: 2210-15.
132. Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry 2002; 73: 529-34. (Pubitemid 35246805)
133. Schreckenberger M, Hä gele S, Seissmeier T, Buchholz HG, Armbrust-Henrich H, Rö sch F, et al. The dopamine D2 receptor ligand 18F-desmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of Parkinsonism. Eur J Nucl Med Mol Imaging 2004; 31: 1128-35. (Pubitemid 39050180)
134. Seibyl J, Jennings D, Tabamo R, Marek K. The role of neuroimaging in the early diagnosis and evaluation of Parkinson's disease. Minerva Med 2005; 96: 353-64. (Pubitemid 41745595)
135. Seibyl J, Jennings D, Tabamo R, Marek K. Unique roles of SPET brain imaging in clinical and research studies. Q J Nucl Med Mol Imaging 2005b; 49: 215-21.
136. Shiba M, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: a case-control study. Mov Disord 2000; 15: 669-77. (Pubitemid 30479619)
137. Shih MC, Amaro E Jr, Ferraz HB, Hoexter MQ, Goulart FO, Wagner J, et al. Neuroimaging of the dopamine transporter in Parkinson's disease: first study using [99mTc]-TRODAT and SPECT in Brazil. Arq Neuropsiquiatr 2006; 64 (3A): 628-34.
138. Stephen PJ, Williamson J. Drug-induced parkinsonism in the elderly. Lancet 1984; 2 (8411): 1082-3. (Pubitemid 15211533)
139. Stiasny-Kolster K, Doerr Y, Mö ller JC, Hö ffken H, Behr TM, Oertel WJ, et al. Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT SPECT. Brain 2005; 128 (Pt 1): 126-37. (Pubitemid 40070527)
140. Stoffers D, Booij J, Bosscher L, Winogrodzka A, Wolters EC, Berendse HW. Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial clinical diagnosis of Parkinson's disease. Eur J Med Mol Imaging 2005; 32: 689-95. (Pubitemid 40897492)
141. Swanson RL, Newberg AB, Acton PD, Siderowf A, Wintering N, Alavi A, et al. Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease. Eur J Med Mol Imaging 2005; 32: 302-7. (Pubitemid 40562121)
142. Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010; 9: 149-58.
143. Teive HA, Troiano AR, Germiniani FM, Werneck LC. Flunarizine and cinnarizine-induced Parkinsonism: a historical and clinical analysis. Parkinsonism Relat Disord 2004; 10: 243-5. (Pubitemid 38534618)
144. Thanvi B, Robinson T. Vascular Parkinsonism-an important cause of par-kinsonism in older people. Age Ageing 2005; 34: 114-9. (Pubitemid 40331090)
145. Thanvi B, Treadwell S. Drug induced Parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J 2009; 85: 322-6.
146. Thobois S, Vingerhoets F, Fraix V, Xie-Brustolin J, Mollion H, Costes N, et al. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch Neurol 2004; 61: 1705-9. (Pubitemid 39463429)
147. Tinazzi M, Ottaviani S, Isaias IU, Pasquin I, Steinmayr M, Vampini C, et al. [123I]FP-CIT SPET imaging in drug-induced Parkinsonism. Mov Disord 2008; 23: 1825-9.
148. Tinazzi M, Antonini A, Bovi T, Pasquin I, Steinmayr M, Moretto G, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced Parkinsonism. J Neurol 2009; 256: 910-15.
149. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic Parkinsonism. Mov Disord 2003; 18 (Suppl. 7): S28-33. (Pubitemid 37336925)
150. Tolosa E, Borght TV, Moreno E. DaTSCANTM Clinically Uncertain Parkinsonian Syndromes Study Group. Accuracy of DaTSCANTM (123I-ioflupane) SPECT in diagnosis of patients with clinically uncertain Parkinsonism: 2-year follow-up of an open-label study. Mov Disord 2007a; 22: 2346-51. (Pubitemid 351155979)
151. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat Disord 2007b; 13 (Suppl): S2-7. (Pubitemid 47444539)
152. Turjanski N, Lees AJ, Brooks DJ. Dopaminergic function in patients with posttraumatic Parkinsonism: an 18F-dopa PET study. Neurology 1997; 49: 183-9. (Pubitemid 27328700)
153. Tzen KY, Lu CS, Yen TC, Wey SP, Ting G. Differential diagnosis of Parkinson's disease and vascular Parkinsonism by 99mTc-TRODAT-1. J Nucl Med 2001; 42: 408-13. (Pubitemid 32207389)
154. Vaamonde-Gamo J, Flores-Barragágan JM, Ibáñez R, Gud?́n M, Hernández A. DaT-SCAN SPECT in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease. Rev Neurol 2005; 41: 276-9. (Pubitemid 47289328)
155. Van Gerpen JA. Drug-induced Parkinsonism. Neurologist 2002; 8: 363-70. (Pubitemid 35365224)
156. Van Laere K, Clerinx K, D'Hondt E, de Groot T, Vandenberghe W. Combined striatal binding and cerebral influx analysis of dynamic 11C-raclopride PET improves early differentiation between multiple-system atrophy and Parkinson disease. J Nucl Med 2010; 51: 588-95.
157. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [123I]b-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson's disease and multiple system atrophy. Mov Disord 2001; 16: 1023-32. (Pubitemid 36041214)
158. Vlaar AM, de Nijs T, Kessels AG, Vreeling FW, Winogrodzka A, Mess WH, et al. Diagnostic value of 123I-ioflupane and 123I-iodobenzamide SPECT scans in 248 patients with Parkinsonian syndromes. Eur Neurol 2008; 59: 258-66. (Pubitemid 351561095)
159. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002; 73: 134-40.
160. Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 2004; 62: 1568-72. (Pubitemid 38608197)
161. Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007; 78: 1176-81. (Pubitemid 350057277)
162. Wang J, Jiang YP, Liu XD, Chen ZP, Yang LQ, Liu CJ, et al. 99mTc-TRODAT-1 SPECT study in early Parkinson's disease and essential tremor. Acta Neurol Scand 2005; 112: 380-5. (Pubitemid 41695717)
163. Weng YH, Yen TC, Chen MC, Kao PF, Tzen KY, Chen RS, et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med 2004; 45: 393-401.
164. Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson's disease with ropinirole versus levo-dopa: the REAL-PET study. Ann Neurol 2003; 54: 93-101. (Pubitemid 36764985)
165. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005; 34: 561-6. (Pubitemid 41699997)
166. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG; MRC Cognitive Function, Ageing Neuropathology Study. Patterns and stages of alpha-synucleinopathy: relevance in a population-based cohort. Neurology 2008; 70: 1042-8.
167. Zijlmans J, Evans A, Fontes F, Katzenschlager R, Gacinovic S, Lees AJ, et al. [123I]FP-spect study in vascular Parkinsonism and Parkinson's disease. Mov Disord 2007; 2: 1278-85. (Pubitemid 47325035)